Accuracy of Whole-Body 18F-FDP-PET for Restaging Malignant Lymphoma Effektivität der Ganzkörper-F-18 Deoxyglukose Positronenemissionstomographie beim Restaging von malignen Lymphomen

P. Mikosch, H. J. Gallowitsch, W. Zinke-Cerwenka, M. Heinisch, W. Pipam, M. Eibl, E. Kresnik, O. Unterweger, W. Linkesch, P. Lind
{"title":"Accuracy of Whole-Body 18F-FDP-PET for Restaging Malignant Lymphoma\n Effektivität der Ganzkörper-F-18 Deoxyglukose Positronenemissionstomographie beim Restaging von malignen Lymphomen","authors":"P. Mikosch,&nbsp;H. J. Gallowitsch,&nbsp;W. Zinke-Cerwenka,&nbsp;M. Heinisch,&nbsp;W. Pipam,&nbsp;M. Eibl,&nbsp;E. Kresnik,&nbsp;O. Unterweger,&nbsp;W. Linkesch,&nbsp;P. Lind","doi":"10.1046/j.1563-2571.2003.03003.x","DOIUrl":null,"url":null,"abstract":"<p><b>Summary:</b><b> Background:</b> The aim of this retrospective study was to evaluate the accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG-PET) images, which were interpreted under daily routine conditions, in patients with Hodgkin's disease (HD) or non-Hodgkin lymphoma (NHL) for restaging after chemotherapy and/or radiotherapy. For this purpose, <sup>18</sup>F-FDG-PET results were compared with morphological imaging methods and the patients’ clinical background.</p><p><b>Methods:</b> 121 PET images of 93 lymphoma patients (44 HD, 49 NHL) were investigated after chemotherapy/radiotherapy. For PET imaging, 160–200 MBq <sup>18</sup>F-FDG was administered intravenously, followed by an infusion of 20 mg Furosemid in 250 mL saline. Whole-body <sup>18</sup>F-FDG-PET images were obtained using a partial-ring PET scanner without attenuation correction. The morphological imaging consisted in computed tomography and ultrasound (CT/US) in all patients, additional MRI in some patients, and iliac crest biopsy in cases of suspicious bone marrow involvement. The standard of reference was composed of biopsy data, clinical status at the time of investigation, and follow-up of at least 12 months. The PET images were evaluated for their sensitivity, specificity and accuracy based on written reports, which were compiled from other imaging data and the clinical history of the patients.</p><p><b>Results:</b> Sensitivity, specificity, and accuracy of <sup>18</sup>F-FDG-PET was 91 %, 81 %, and 85 %; of CT/US, 88 %, 35 %, 56 %, respectively. Major sources of error in <sup>18</sup>F-FDG-PET were due to asymmetric muscular hypermetabolism and inflammatory lesions misinterpreted as persistent viable lymphoma tissue. Furthermore, secondary malignancies other than lymphomas were another reason for misinterpretations of <sup>18</sup>F-FDG-PET studies.</p><p><b>Conclusions:</b> <sup>18</sup>F-FDG-PET showed a comparable sensitivity but a higher specificity and accuracy compared with CT/US. To achieve a high accuracy in <sup>18</sup>F-FDG-PET, the nuclear medicine specialist needs imaging and clinical data as background information, which can only be acquired through close co-operation with the referring clinicians. Pharmacological muscular relaxation in the course of <sup>18</sup>F-FDG-PET imaging may be advisable, as nonspecific muscular hypermetabolism was one of the problems at the image readings and a source of incorrect <sup>18</sup>F-FDG-PET interpretations.</p>","PeriodicalId":6945,"journal":{"name":"Acta medica Austriaca","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2008-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/j.1563-2571.2003.03003.x","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica Austriaca","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1046/j.1563-2571.2003.03003.x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 27

Abstract

Summary: Background: The aim of this retrospective study was to evaluate the accuracy of fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) images, which were interpreted under daily routine conditions, in patients with Hodgkin's disease (HD) or non-Hodgkin lymphoma (NHL) for restaging after chemotherapy and/or radiotherapy. For this purpose, 18F-FDG-PET results were compared with morphological imaging methods and the patients’ clinical background.

Methods: 121 PET images of 93 lymphoma patients (44 HD, 49 NHL) were investigated after chemotherapy/radiotherapy. For PET imaging, 160–200 MBq 18F-FDG was administered intravenously, followed by an infusion of 20 mg Furosemid in 250 mL saline. Whole-body 18F-FDG-PET images were obtained using a partial-ring PET scanner without attenuation correction. The morphological imaging consisted in computed tomography and ultrasound (CT/US) in all patients, additional MRI in some patients, and iliac crest biopsy in cases of suspicious bone marrow involvement. The standard of reference was composed of biopsy data, clinical status at the time of investigation, and follow-up of at least 12 months. The PET images were evaluated for their sensitivity, specificity and accuracy based on written reports, which were compiled from other imaging data and the clinical history of the patients.

Results: Sensitivity, specificity, and accuracy of 18F-FDG-PET was 91 %, 81 %, and 85 %; of CT/US, 88 %, 35 %, 56 %, respectively. Major sources of error in 18F-FDG-PET were due to asymmetric muscular hypermetabolism and inflammatory lesions misinterpreted as persistent viable lymphoma tissue. Furthermore, secondary malignancies other than lymphomas were another reason for misinterpretations of 18F-FDG-PET studies.

Conclusions: 18F-FDG-PET showed a comparable sensitivity but a higher specificity and accuracy compared with CT/US. To achieve a high accuracy in 18F-FDG-PET, the nuclear medicine specialist needs imaging and clinical data as background information, which can only be acquired through close co-operation with the referring clinicians. Pharmacological muscular relaxation in the course of 18F-FDG-PET imaging may be advisable, as nonspecific muscular hypermetabolism was one of the problems at the image readings and a source of incorrect 18F-FDG-PET interpretations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
189% 9%的9%用于人体实验
摘要:背景:本回顾性研究的目的是评估氟-18氟脱氧葡萄糖正电子发射断层扫描(18F-FDG-PET)图像的准确性,这些图像是在日常条件下解释的,用于霍奇金病(HD)或非霍奇金淋巴瘤(NHL)患者化疗和/或放疗后的再分期。为此,将18F-FDG-PET结果与形态学成像方法和患者临床背景进行比较。方法:对93例淋巴瘤患者(恶性淋巴瘤44例,非恶性淋巴瘤49例)化疗/放疗后的121张PET图像进行分析。PET成像时,静脉注射160-200 MBq 18F-FDG,然后在250 mL生理盐水中注入20 mg速尿。全身18F-FDG-PET图像使用不带衰减校正的部分环形PET扫描仪获得。形态学成像包括所有患者的计算机断层扫描和超声(CT/US),部分患者的MRI,以及可疑骨髓受累的髂嵴活检。参考标准包括活检数据、调查时的临床状况和至少12个月的随访。根据其他影像学资料和患者的临床病史编写的书面报告,评估PET图像的敏感性、特异性和准确性。结果:18F-FDG-PET的灵敏度、特异度和准确度分别为91%、81%和85%;CT/US分别为88%、35%、56%。18F-FDG-PET的主要误差来源是由于不对称的肌肉高代谢和炎性病变被误解为持续存活的淋巴瘤组织。此外,淋巴瘤以外的继发性恶性肿瘤是18F-FDG-PET研究被误解的另一个原因。结论:与CT/US相比,18F-FDG-PET具有相当的敏感性,但具有更高的特异性和准确性。为了实现18F-FDG-PET的高精度,核医学专家需要影像和临床数据作为背景信息,这些信息只能通过与转诊临床医生密切合作才能获得。在18F-FDG-PET成像过程中,药物肌肉松弛可能是可取的,因为非特异性肌肉高代谢是图像读取的问题之一,也是错误18F-FDG-PET解释的来源。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
ESC Congress 2003 – European Society of Cardiology EANM ’03 – Annual Congress of the European Association of Nuclear Medicine Editorial: Stellungnahme zum Marktrückzug von Cerivastatin Therapie der endokrinen Orbitopathie mit Somatostatin-Analoga bei Patienten mit positivem Octreo-Scan The Influence of Obesity on the Frequency and Distribution of Medication Der Einfluß der Adipositas auf die Häufigkeit und Verteilung der Medikation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1